IMNM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

727.27K

-75.01%

-0.600

-45.93%

850.00K

-68.96%

-0.598

+14.96%

500.00K

-82.91%

-0.618

+23.56%

Estimates Revision

The market is revising Downward the revenue expectations for Immunome, Inc. (IMNM) for FY2025, with the revenue forecasts being adjusted by -8.98% over the past three months. During the same period, the stock price has changed by 47.86%.

Revenue Estimates for FY2025

Revise Downward

-8.98%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+6.35%

In Past 3 Month

Stock Price

Go Up

+47.86%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast IMNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNM is 23.57 USD with a low forecast of 18.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

18.00

Averages

23.57

High

33.00

Current: 0.000

Low

18.00

Averages

23.57

High

33.00

Guggenheim

Buy

upgrade

$25 -> $35

2025-12-16

Reason

Guggenheim

Price Target

$25 -> $35

2025-12-16

upgrade

Buy

Reason

Guggenheim raised the firm's price target on Immunome to $35 from $25 and keeps a Buy rating on the shares after the company reported positive top-line Phase 3 trial results for varegacestat. The firm believes approval likelihood is high and that varegacestat is well-positioned to capture the majority share in the a potential $1B-$2B DT market in the U.S.

Evercore ISI

NULL

Outperform

upgrade

$18 -> $40

2025-12-16

Reason

Evercore ISI

Price Target

$18 -> $40

2025-12-16

upgrade

NULL

Outperform

Reason

Evercore ISI raised the firm's price target on Immunome to $40 from $18 and keeps an Outperform rating on the shares. The "overwhelmingly positive" results from the RINGSIDE trial bolstered confidence in varegacestat's potential as a leading treatment for desmoid tumors, the analyst tells investors.

Lake Street

Buy

maintain

$22 -> $32

2025-12-16

Reason

Lake Street

Price Target

$22 -> $32

2025-12-16

maintain

Buy

Reason

Lake Street raised the firm's price target on Immunome to $32 from $22 and keeps a Buy rating on the shares after the RINGSIDE trial reached high levels of statistical significance on its key efficacy endpoints. These data "appear to be a win on all fronts and are likely to propel varegacestat to the class leader shortly after launch," the analyst tells investors.

Leerink

Outperform

upgrade

$38 -> $40

2025-12-15

Reason

Leerink

Price Target

$38 -> $40

2025-12-15

upgrade

Outperform

Reason

Leerink raised the firm's price target on Immunome to $40 from $38 and keeps an Outperform rating on the shares. Varegacstat Phase 3 success has moved the firm's investment thesis ringside for commercial launch and execution, where management has as strong track record of success, and opens the door for a pipeline unveiling, the analyst tells investors in a research note. The firm added that while longer-term treatment duration for the varegacestat class remains an outstanding commercial question, it believes the new data unlock a roughly $780M peak revenue opportunity.

Stephens

Overweight

maintain

$25 -> $33

2025-11-17

Reason

Stephens

Price Target

$25 -> $33

2025-11-17

maintain

Overweight

Reason

Stephens raised the firm's price target on Immunome to $33 from $25 and keeps an Overweight rating on the shares ahead of the company presenting top-line data from their Phase 3 RINGSIDE Part B program of varegacestat for the treatment of desmoid tumors by year-end. Based varegacestat having demonstrated a best-in-class overall response rate and safety profile in Phase 2, the firm has bolstered conviction in the asset's longer-term potential in competing against the current standard of care and revised its peak penetration estimates, the analyst tells investors.

Goldman Sachs

initiated

$26

2025-09-22

Reason

Goldman Sachs

Price Target

$26

2025-09-22

initiated

Reason

Goldman Sachs initiated coverage of Immunome with a Buy rating and $26 price target. The firm says Immunome is developing best- or first-in-class targeted oncology therapeutics. Goldman is positive into the Phase 3 RINGSIDE results in patients with desmoid tumors, with data expected at the end of 2025. Varegacestat is \"differentiated\" over Merck KGaA's Ogsiveo, with best-in-class potential, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Immunome Inc (IMNM.O) is -8.46, compared to its 5-year average forward P/E of -5.54. For a more detailed relative valuation and DCF analysis to assess Immunome Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.54

Current PE

-8.46

Overvalued PE

-2.23

Undervalued PE

-8.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.03

Current EV/EBITDA

-8.76

Overvalued EV/EBITDA

0.85

Undervalued EV/EBITDA

-2.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

153.11

Current PS

1004.20

Overvalued PS

473.83

Undervalued PS

-167.61

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 113.26% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 577.15% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 113.26% over the last month.

Sold

Bought

IMNM News & Events

Events Timeline

No data

News

5.0

2025-12-19NASDAQ.COM

Insider Buying Update for Friday, December 19: IMNM and S

8.0

2025-12-19NASDAQ.COM

Initial Week of IMNM Options Trading for February 2026

8.5

2025-12-17Newsfilter

Immunome Prices 18.625M Share Offering at $21.50, Raising Approximately $400 Million

People Also Watch

Frequently Asked Questions

What is Immunome Inc (IMNM) stock price today?

The current price of IMNM is 21.07 USD — it has increased 3.03 % in the last trading day.

What is Immunome Inc (IMNM)'s business?

Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.

What is the price predicton of IMNM Stock?

What is Immunome Inc (IMNM)'s revenue for the last quarter?

Immunome Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Immunome Inc (IMNM)'s earnings per share (EPS) for the last quarter?

Immunome Inc. EPS for the last quarter amounts to -0.65 USD, decreased -16.67 % YoY.

What changes have occurred in the market's expectations for Immunome Inc (IMNM)'s fundamentals?

How many employees does Immunome Inc (IMNM). have?

Immunome Inc (IMNM) has 118 emplpoyees as of January 11 2026.

What is Immunome Inc (IMNM) market cap?

Today IMNM has the market capitalization of 2.32B USD.